Nonalcoholic fatty liver disease and aging: Epidemiology to management

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14185-14204

  Bertolotti, Marco ^a   Lonardo, Amedeo ^a   Mussi, Chiara ^a   Baldelli, Enrica ^a   Pellegrini, Elisa ^a   Ballestri, Stefano ^a,b   Romagnoli, Dante ^a   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Pavullo Hospital   (Italy)

Author keywords

Adipose tissue; Aortic valve sclerosis; Arrhythmia; Atherosclerosis; Autonomic dysfunction; Cirrhosis; Dementia; Falls; Frailty; Hepatocellular carcinoma; Microbiota; Nuclear receptors; Pathogenesis; Sarcopenia; Treatment

Indexed keywords

ALPHA TOCOPHEROL; PREBIOTIC AGENT; PROBIOTIC AGENT; VITAMIN D;

ADIPOSE TISSUE; AGE DISTRIBUTION; AGING; AUTONOMIC DYSFUNCTION; CANCER RISK; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; FRAIL ELDERLY; GENETIC ANALYSIS; GERIATRIC DISORDER; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; HYPERTENSION; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIVER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MEDICAL HISTORY; METABOLIC DISORDER; MICROFLORA; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PHYSICAL ACTIVITY; POLYPHARMACY; POPULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOPENIA; SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); ADULT; AGE; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; GERIATRIC ASSESSMENT; HOST PATHOGEN INTERACTION; INTESTINE; LIFESTYLE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR DISEASES; COMORBIDITY; DEMENTIA; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; LIFE STYLE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYPHARMACY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SARCOPENIA;

EID: 84910147550     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14185     Document Type: Review

References (251)

1. World Health Organization. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Disease. Geneva, Switzerland: World Health Organization, 2009
2. Jones K, Timchenko L, Timchenko NA. The role of CUGBP1 in age-dependent changes of liver functions. Ageing Res Rev 2012; 11: 442-449 [PMID: 22446383 DOI: 10.1016/j.arr.2012.02.007]
3. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology 2009; 55: 607-613 [PMID: 19690397 DOI: 10.1159/000235677]
4. Mak KM, Chu E, Lau KH, Kwong AJ. Liver fibrosis in elderly cadavers: localization of collagen types I, III, and IV, α-smooth muscle actin, and elastic fibers. Anat Rec (Hoboken) 2012; 295: 1159-1167 [PMID: 22644959 DOI: 10.1002/ar.22504]
5. Anantharaju A, Feller A, Chedid A. Aging Liver. A review. Gerontology 2002; 48: 343-353 [PMID: 12393949]
6. Jin J, Wang GL, Timchenko L, Timchenko NA. GSK3beta and aging liver. Aging (Albany NY) 2009; 1: 582-585 [PMID: 20157540]
7. Singh P, Goode T, Dean A, Awad SS, Darlington GJ. Elevated interferon gamma signaling contributes to impaired regeneration in the aged liver. J Gerontol A Biol Sci Med Sci 2011; 66: 944-956 [PMID: 21719609 DOI: 10.1093/gerona/glr094]
8. Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 2008; 14: 959-965 [PMID: 18690243 DOI: 10.1038/nm.1851]
9. Cuervo AM. Cell biology. Autophagy's top chef. Science 2011; 332: 1392-1393 [PMID: 21680833 DOI: 10.1126/science.1208607]
10. Mallikarjuna K, Shanmugam KR, Nishanth K, Wu MC, Hou CW, Kuo CH, Reddy KS. Alcohol-induced deterioration in primary antioxidant and glutathione family enzymes reversed by exercise training in the liver of old rats. Alcohol 2010; 44: 523-529 [PMID: 20705416 DOI: 10.1016/j.alcohol.2010.07.004]
11. Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res 2011; 2011: 831536 [PMID: 21918648 DOI: 10.1155/2011/831536]
12. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19: 5177-5192 [PMID: 23432668]
13. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889 [PMID: 17402991]
14. Ovchinsky N, Lavine JE. A critical appraisal of advances in pediatric nonalcoholic Fatty liver disease. Semin Liver Dis 2012; 32: 317-324 [PMID: 23397532 DOI: 10.1055/s-0032-1329905]
15. Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health 2012; 51: 305-312 [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010]
16. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006; 44: 1196-1207 [PMID: 16618516]
17. Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012; 57: 1305-1311 [PMID: 22871499 DOI: 10.1016/j.jhep.2012.07.028]
18. Wang Z, Xu M, Peng J, Jiang L, Hu Z, Wang H, Zhou S, Zhou R, Hultström M, Lai EY. Prevalence and associated metabolic factors of fatty liver disease in the elderly. Exp Gerontol 2013; 48: 705-709 [PMID: 23721951 DOI: 10.1016/j.exger.2013.05.059]
19. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]
20. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of nonalcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007-1019 [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021]
21. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149 [PMID: 3047469]
22. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-961 [PMID: 14614602]
23. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, Chen SY. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106-1110 [PMID: 12717867]
24. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-514 [PMID: 16006003]
25. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40: 745-752 [PMID: 16940890]
26. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-143 [PMID: 16706825]
27. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856-863 [PMID: 16911469]
28. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13: 6419-6424 [PMID: 18081233]
29. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47: 239-244 [PMID: 17400323]
30. Miyaaki H, Ichikawa T, Nakao K, Yatsuhashi H, Furukawa R, Ohba K, Omagari K, Kusumoto Y, Yanagi K, Inoue O, Kinoshita N, Ishibashi H, Yano M, Eguchi K. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008; 28: 519-524 [PMID: 17976158]
31. Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, Gao Z, Yu X. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol 2012; 12: 123 [PMID: 22978800 DOI: 10.1186/1471-230X-12-123]
32. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, Chan FK, Chan HL. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415 [PMID: 21846782 DOI: 10.1136/gutjnl-2011-300342]
33. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18: 237-243 [PMID: 22294826 DOI: 10.3748/wjg.v18.i3.237]
34. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-595 [PMID: 22328022 DOI: 10.1007/s00535-012-0533-z]
35. Al-hamoudi W, El-Sabbah M, Ali S, Altuwaijri M, Bedewi M, Adam M, Alhammad A, Sanai F, Alswat K, Abdo A. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Ann Saudi Med 2012; 32: 288-292 [PMID: 22588441 DOI: 10.5144/0256-4947.2012.288]
36. Foster T, Anania FA, Li D, Katz R, Budoff M. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci 2013; 58: 2392-2398 [PMID: 23546700 DOI: 10.1007/s10620-013-2652-7]
37. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 2013; 108: 1299-1304 [PMID: 23567356 DOI: 10.1038/ajg.2013.104]
38. Yan J, Xie W, Ou WN, Zhao H, Wang SY, Wang JH, Wang Q, Yang YY, Feng X, Cheng J. Epidemiological survey and risk factor analysis of fatty liver disease of adult residents, Beijing, China. J Gastroenterol Hepatol 2013; 28: 1654-1659 [PMID: 23731053 DOI: 10.1111/jgh.12290]
39. Lonardo A, Lombardini S, Scaglioni F, Ballestri S, Verrone AM, Bertolotti M, Carulli L, Ganazzi D, Carulli N, Loria P. Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol 2006; 12: 5826-5833 [PMID: 17007049]
40. Bedogni G, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-1391 [PMID: 17685472]
41. Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, Alumà A, Casas JD, Sánchez C, Gil D, Aubà J, Tibau A, Canut S, Bernad J, Aizpurua MM. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010; 22: 24-32 [PMID: 19730384 DOI: 10.1097/MEG.0b013e32832fcdf0]
42. Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Manzato E, Cattin L, Fellin R, Averna MR, Notarbartolo A. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol 2013; 50: 241-249 [PMID: 22684314 DOI: 10.1007/s00592-012-0406-1]
43. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570]
44. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91: 319-327 [PMID: 23117851 DOI: 10.1097/MD.0b013e3182779d49]
45. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: 769-780 [PMID: 21987488 DOI: 10.1002/hep.24726]
46. North KE, Graff M, Franceschini N, Reiner AP, Feitosa MF, Carr JJ, Gordon-Larsen P, Wojczynski MK, Borecki IB. Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European American and African American participants of the NHLBI family heart study. Eur J Gastroenterol Hepatol 2012; 24: 9-16 [PMID: 21900826 DOI: 10.1097/MEG.0b013e32834a94fb]
47. Nakajima T, Nakashima T, Yamaoka J, Shibuya A, Itoh Y, Yoshikawa T. Age is a negative, and visceral fat accumulation is a positive, contributor to hepatic steatosis, regardless of the fibrosis progression in Non-alcoholic Fatty Liver Disease. J Gastroenterol Hepatol Res 2012; 1: 315-319
48. Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P. Gender, fatty liver and GGT. Hepatology 2006; 44: 278-279 [PMID: 16799969]
49. van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, Wu LE, McLeod D, Bugianesi E, Komuta M, Roskams T, Liddle C, Hebbard L, George J. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology 2013; 57: 2180-2188 [PMID: 22996622 DOI: 10.1002/hep.26072]
50. Kagansky N, Levy S, Keter D, Rimon E, Taiba Z, Fridman Z, Berger D, Knobler H, Malnick S. Non-alcoholic fatty liver disease - a common and benign finding in octogenarian patients. Liver Int 2004; 24: 588-594 [PMID: 15566509 DOI: 10.1111/j.1478-3231.2004.0969.x]
51. Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013; 58: 1644-1654 [PMID: 23686698 DOI: 10.1002/hep.26465]
52. Suzuki A, Diehl AM. Should nonalcoholic fatty liver disease be treated differently in elderly patients? Nat Clin Pract Gastroenterol Hepatol 2005; 2: 208-209 [PMID: 16265200]
53. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302 DOI: 10.3109/07853890.2010.518623]
54. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]
55. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271 [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034.x]
56. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 [PMID: 7382552]
57. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669 [PMID: 10051466]
58. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40: 578-584 [PMID: 15030972]
59. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842]
60. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80 [PMID: 2295475]
61. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep.23594]
62. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]
63. Kodama K, Tokushige K, Hashimoto E, Taniai M, Shiratori K. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 Suppl 1: E247-E252 [PMID: 23320802 DOI: 10.1111/j.1530-0277.2012.01900.x]
64. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859 [PMID: 19115377 DOI: 10.1002/hep.22734]
65. Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 2013; 28: 848-854 [PMID: 23302015 DOI: 10.1111/jgh.12116]
66. Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009; 7: 580-585 [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001]
67. Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F, Borzio M, Caturelli E, Di Nolfo MA, Frigerio M, Brancaccio G, Gaeta GB. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis 2011; 43: 875-880 [PMID: 21684821 DOI: 10.1016/j.dld.2011.05.002]
68. Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99: 1470-1476 [PMID: 15307862]
69. Tajiri K, Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol 2013; 19: 8459-8467 [PMID: 24379563 DOI: 10.3748/wjg.v19.i46.8459]
70. Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res 2011; 42: 337-353 [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004]
71. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011; 17: 3785-3794 [PMID: 21987620 DOI: 10.3748/wjg.v17.i33.3785]
72. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230: 258-267 [PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052]
73. Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008; 115: 1-12 [PMID: 19016656 DOI: 10.1042/CS20070311]
74. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007; 17: 684-698 [PMID: 17560098]
75. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724]
76. Akahoshi M, Amasaki Y, Soda M, Tominaga T, Ichimaru S, Nakashima E, Seto S, Yano K. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001; 24: 337-343 [PMID: 11510744]
77. Li M, Xu Y, Xu M, Ma L, Wang T, Liu Y, Dai M, Chen Y, Lu J, Liu J, Bi Y, Ning G. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 2012; 97: 2033-2038 [PMID: 22466338 DOI: 10.1210/jc.2011-3010]
78. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-836 [PMID: 21339204 DOI: 10.1136/gut.2011.237974]
79. Floreani A. Liver diseases in the elderly: an update. Dig Dis 2007; 25: 138-143 [PMID: 17468549]
80. Frith J, Jones D, Newton JL. Chronic liver disease in an ageing population. Age Ageing 2009; 38: 11-18 [PMID: 19029099 DOI: 10.1093/ageing/afn242]
81. Marchesini G, Bua V, Brunori A, Bianchi G, Pisi P, Fabbri A, Zoli M, Pisi E. Galactose elimination capacity and liver volume in aging man. Hepatology 1988; 8: 1079-1083 [PMID: 3417228]
82. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994; 49: M252-M257 [PMID: 7963277]
83. Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, Capocaccia L, Menotti A, Okolicsanyi L, Ricci G, Lalloni L, Mariotti S, Sama C, Scafato E. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology 1997; 26: 809-818 [PMID: 9328297]
84. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991; 87: 591-596 [PMID: 1991842]
85. Einarsson K, Nilsell K, Leijd B, Angelin B. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med 1985; 313: 277-282 [PMID: 4010739]
86. Bertolotti M, Abate N, Bertolotti S, Loria P, Concari M, Messora R, Carubbi F, Pinetti A, Carulli N. Effect of aging on cholesterol 7 alpha-hydroxylation in humans. J Lipid Res 1993; 34: 1001-1007 [PMID: 8354947]
87. Bertolotti M, Mussi C, Pellegrini E, Magni A, Del Puppo M, Ognibene S, Carulli L, Anzivino C, Baldelli E, Loria P, Carulli N. Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. Clin Interv Aging 2014; 9: 425-432 [PMID: 24669190 DOI: 10.2147/CIA.S57714]
88. Sheedfar F, Di Biase S, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes? Aging Cell 2013; 12: 950-954 [PMID: 23815295 DOI: 10.1111/acel.12128]
89. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-379 [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005]
90. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761 [PMID: 16968800]
91. Lonardo A, Caldwell,CH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Rev Endocrinol Metab 2010; 5: 403-423 [DOI: 10.1586/eem.10.5]
92. Barzilai N, Ferrucci L. Insulin resistance and aging: a cause or a protective response? J Gerontol A Biol Sci Med Sci 2012; 67: 1329-1331 [PMID: 22859390 DOI: 10.1093/gerona/gls145]
93. Ceda GP, Dall'Aglio E, Magnacavallo A, Vargas N, Fontana V, Maggio M, Valenti G, Lee PD, Hintz RL, Hoffman AR. The insulin-like growth factor axis and plasma lipid levels in the elderly. J Clin Endocrinol Metab 1998; 83: 499-502 [PMID: 9467564]
94. Paolisso G, Tagliamonte MR, Rizzo MR, Giugliano D. Advancing age and insulin resistance: new facts about an ancient history. Eur J Clin Invest 1999; 29: 758-769 [PMID: 10469164]
95. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Ble A, Egan J, Paolisso G, Najjar S, Jeffrey Metter E, Valenti G, Guralnik JM, Ferrucci L. Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc 2006; 54: 1832-1838 [PMID: 17198487]
96. Bertolotti M, Gabbi C, Anzivino C, Crestani M, Mitro N, Del Puppo M, Godio C, De Fabiani E, Macchioni D, Carulli L, Rossi A, Ricchi M, Loria P, Carulli N. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur J Clin Invest 2007; 37: 501-508 [PMID: 17537158]
97. Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugarà M, Procopio T, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 2011; 96: E1640-E1644 [PMID: 21816784 DOI: 10.1210/jc.2011-1227]
98. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6: 236-247 [PMID: 19347015 DOI: 10.1038/nrgastro.2009.33]
99. Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol 2013; 19: 6735-6743 [PMID: 24187449 DOI: 10.3748/wjg.v19.i40.6735]
100. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865]
101. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726-735 [PMID: 24316260 DOI: 10.1053/j.gastro.2013.11.049.[Epub]
102. Sanguino E, Roglans N, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol 2005; 145: 853-861 [PMID: 15912134 DOI: 10.1038/sj.bjp.0706260]
103. Kuhla A, Blei T, Jaster R, Vollmar B. Aging is associated with a shift of fatty metabolism toward lipogenesis. J Gerontol A Biol Sci Med Sci 2011; 66: 1192-1200 [PMID: 21835806 DOI: 10.1093/gerona/glr124]
104. Masetti M, Bianchi G, Gianotti G, Giovagnoli M, Vizioli L, Zorzi V, Rossi V, Forti P, Zoli M. Adipocyte-fatty acid binding protein and non-alcoholic fatty liver disease in the elderly. Aging Clin Exp Res 2014; 26: 241-247 [PMID: 24150574]
105. Fontana L, Zhao E, Amir M, Dong H, Tanaka K, Czaja MJ. Aging promotes the development of diet-induced murine steatohepatitis but not steatosis. Hepatology 2013; 57: 995-1004 [PMID: 23081825]
106. Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Bacalini MG, Garagnani P, Giuliani C, Fontanesi E, Ostan R, Bucci L, Sevini F, Yani SL, Barbieri A, Lomartire L, Borelli V, Vianello D, Bellavista E, Martucci M, Cevenini E, Pini E, Scurti M, Biondi F, Santoro A, Capri M, Franceschi C. Immune system, cell senescence, aging and longevity - inflammaging reappraised. Curr Pharm Des 2013; 19: 1675-1679 [PMID: 23589904]
107. Tarantino G, Savastano S, Colao A. Hepatic steatosis, lowgrade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 2010; 16: 4773-4783 [PMID: 20939105]
108. Savastano S, Di Somma C, Pizza G, De Rosa A, Nedi V, Rossi A, Orio F, Lombardi G, Colao A, Tarantino G. Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J Transl Med 2011; 9: 136 [PMID: 21846339 DOI: 10.1186/1479-5876-9-136]
109. Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 6198-6202 [PMID: 17036395]
110. García-Monzón C, Lo Iacono O, Mayoral R, González-Rodríguez A, Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, Vargas-Castrillón J, Casado M, Boscá L, Valverde AM, Martín-Sanz P. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol 2011; 54: 142-152 [PMID: 20888662 DOI: 10.1016/j.jhep.2010.06.021]
111. Tarantino G, Scopacasa F, Colao A, Capone D, Tarantino M, Grimaldi E, Savastano S. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. World J Gastroenterol 2011; 17: 5280-5288 [PMID: 22219597 DOI: 10.3748/wjg.v17.i48.5280]
112. Nakamura Y, Sekikawa A, Kadowaki T, Kadota A, Kadowaki S, Maegawa H, Kita Y, Evans RW, Edmundowicz D, Curb JD, Ueshima H. Visceral and subcutaneous adiposity and adiponectin in middle-aged Japanese men: the ERA JUMP study. Obesity (Silver Spring) 2009; 17: 1269-1273 [PMID: 19584883 DOI: 10.1038/oby.2009.3]
113. Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL. Aging and regional differences in fat cell progenitors - a mini-review. Gerontology 2011; 57: 66-75 [PMID: 20110661 DOI: 10.1159/000279755]
114. Cartwright MJ, Schlauch K, Lenburg ME, Tchkonia T, Pirtskhalava T, Cartwright A, Thomou T, Kirkland JL. Aging, depot origin, and preadipocyte gene expression. J Gerontol A Biol Sci Med Sci 2010; 65: 242-251 [PMID: 20106964 DOI: 10.1093/gerona/glp213]
115. Bambace C, Sepe A, Zoico E, Telesca M, Olioso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M. Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels 2014; 29: 42-48 [PMID: 23296264]
116. Stramaglia G, Greco A, Guglielmi G, De Matthaeis A, Vendemiale GL. Echocardiography and dual-energy x-ray absorptiometry in the elderly patients with metabolic syndrome: a comparison of two different tecniques to evaluate visceral fat distribution. J Nutr Health Aging 2010; 14: 6-10 [PMID: 20082047]
117. Bertrand HA, Lynd FT, Masoro EJ, Yu BP. Changes in adipose mass and cellularity through the adult life of rats fed ad libitum or a life-prolonging restricted diet. J Gerontol 1980; 35: 827-835 [PMID: 7440923]
118. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD, Kirkland JL. Fat tissue, aging, and cellular senescence. Aging Cell 2010; 9: 667-684 [PMID: 20701600 DOI: 10.1111/j.1474-9726.2010.00608.x]
119. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Näslund E, Britton T, Concha H, Hassan M, Rydén M, Frisén J, Arner P. Dynamics of fat cell turnover in humans. Nature 2008; 453: 783-787 [PMID: 18454136 DOI: 10.1038/nature06902]
120. Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6: 343-368 [PMID: 18327995 DOI: 10.1586/14779072.6.3.343]
121. Guo W, Pirtskhalava T, Tchkonia T, Xie W, Thomou T, Han J, Wang T, Wong S, Cartwright A, Hegardt FG, Corkey BE, Kirkland JL. Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab 2007; 292: E1041-E1051 [PMID: 17148751]
122. Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009; 24: 830-840 [PMID: 19207680 DOI: 10.1111/j.1440-1746.2008.05733.x]
123. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, Kotani H, Yamaoka S, Miyake K, Aoe S, Kamei Y, Ogawa Y. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27: 84-91 [PMID: 17082484]
124. Tang QQ, Zhang JW, Daniel Lane M. Sequential gene promoter interactions of C/EBPbeta, C/EBPalpha, and PPARgamma during adipogenesis. Biochem Biophys Res Commun 2004; 319: 235-239 [PMID: 15158467]
125. Kirkland JL, Tchkonia T, Pirtskhalava T, Han J, Karagiannides I. Adipogenesis and aging: does aging make fat go MAD? Exp Gerontol 2002; 37: 757-767 [PMID: 12175476]
126. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism - novel insights from genome-wide studies. FEBS Lett 2010; 584: 3242-3249 [PMID: 20542036 DOI: 10.1016/j.febslet.2010.06.010]
127. Floyd ZE, Stephens JM. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARã. Biochim Biophys Acta 2012; 1822: 1090-1095 [PMID: 22504298 DOI: 10.1016/j.bbadis.2012.03.014]
128. Gerin I, Dolinsky VW, Shackman JG, Kennedy RT, Chiang SH, Burant CF, Steffensen KR, Gustafsson JA, MacDougald OA. LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 2005; 280: 23024-23031 [PMID: 15831500]
129. Finelli C, Sommella L, Gioia S, La Sala N, Tarantino G. Should visceral fat be reduced to increase longevity? Ageing Res Rev 2013; 12: 996-1004 [PMID: 23764746 DOI: 10.1016/j.arr.2013.05.007]
130. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res 2009; 16: 1-12 [PMID: 19147530 DOI: 10.1093/dnares/dsn033]
131. Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 1974; 27: 961-979 [PMID: 4598229]
132. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-810 [PMID: 17943116]
133. de Vos WM, Nieuwdorp M. Genomics: A gut prediction. Nature 2013; 498: 48-49 [PMID: 23719383 DOI: 10.1038/nature12251]
134. Bauer E, Williams BA, Smidt H, Verstegen MW, Mosenthin R. Influence of the gastrointestinal microbiota on development of the immune system in young animals. Curr Issues Intest Microbiol 2006; 7: 35-51 [PMID: 16875418]
135. Rolfe RD. Colonization resistance. Gastrointestinal Microbiolog. In: Mackie RI, White BA, Isaacson RE, editors. London: Chapman and Hall, 1997: 501-536
136. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. JPEN J Parenter Enteral Nutr 1997; 21: 357-365 [PMID: 9406136]
137. Deguchi Y, Morishita T, Mutai M. Comparative studies on synthesis of water-soluble vitamins among human species of bifidobacteria. Agric Biol Chem 1985; 49: 13-19
138. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785 [PMID: 17699621]
139. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33 [PMID: 17631127]
140. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 [PMID: 17183312]
141. Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P. Aging of the human metaorganism: the microbial counterpart. Age (Dordr) 2012; 34: 247-267 [PMID: 21347607 DOI: 10.1007/s11357-011-9217-5]
142. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkïla J, Monti D, Satokari R, Franceschi C, Brigidi P, De Vos W. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5: e10667 [PMID: 20498852 DOI: 10.1371/journal.pone.0010667]
143. O'Toole PW, Claesson MJ. Gut microbiota: Changes throughout the lifespan from infancy to elderly. Int Dairy J 2010; 20: 281-291
144. Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O'Sullivan O, Fitzgerald GF, Deane J, O'Connor M, Harnedy N, O'Connor K, O'Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O'Toole PW. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488: 178-184 [PMID: 22797518 DOI: 10.1038/nature11319]
145. Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, Cresci A, Silvi S, Orpianesi C, Verdenelli MC, Clavel T, Koebnick C, Zunft HJ, Doré J, Blaut M. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006; 72: 1027-1033 [PMID: 16461645]
146. van Tongeren SP, Slaets JP, Harmsen HJ, Welling GW. Fecal microbiota composition and frailty. Appl Environ Microbiol 2005; 71: 6438-6442 [PMID: 16204576]
147. Lahtinen SJ, Tammela L, Korpela J, Parhiala R, Ahokoski H, Mykkänen H, Salminen SJ. Probiotics modulate the Bifidobacterium microbiota of elderly nursing home residents. Age (Dordr) 2009; 31: 59-66 [PMID: 19234769 DOI: 10.1007/s11357-008-9081-0]
148. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4586-4591 [PMID: 20571116 DOI: 10.1073/pnas.1000097107]
149. Cheng J, Palva AM, de Vos WM, Satokari R. Contribution of the intestinal microbiota to human health: from birth to 100 years of age. Curr Top Microbiol Immunol 2013; 358: 323-346 [PMID: 22094893 DOI: 10.1007/82-2011-189]
150. Biagi E, Candela M, Turroni S, Garagnani P, Franceschi C, Brigidi P. Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res 2013; 69: 11-20 [PMID: 23079287 DOI: 10.1016/j.phrs.2012.10.005]
151. Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. Immunity 2009; 31: 389-400 [PMID: 19766082 DOI: 10.1016/j.immuni.2009.08.012]
152. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-1925 [PMID: 15790845]
153. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 2008; 23: 64-74 [PMID: 18400689 DOI: 10.1152/physiol.00040.2007]
154. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-323 [PMID: 19343057 DOI: 10.1038/nri2515]
155. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108 [PMID: 21885731 DOI: 10.1126/science.1208344]
156. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249 [PMID: 22972297 DOI: 10.1038/nature11552]
157. Boyce JM, Shone GR. Effects of ageing on smell and taste. Postgrad Med J 2006; 82: 239-241 [PMID: 16597809]
158. Gupta A, Epstein JB, Sroussi H. Hyposalivation in elderly patients. J Can Dent Assoc 2006; 72: 841-846 [PMID: 17109806]
159. Laurin D, Brodeur JM, Bourdages J, Vallée R, Lachapelle D. Fibre intake in elderly individuals with poor masticatory performance. J Can Dent Assoc 1994; 60: 443-446, 449 [PMID: 8004522]
160. Elphick HL, Elphick DA, Sanders DS. Small bowel bacterial overgrowth. An underrecognized cause of malnutrition in older adults. Geriatrics 2006; 61: 21-26 [PMID: 16989544]
161. Oudshoorn C, van der Cammen TJ, McMurdo ME, van Leeuwen JP, Colin EM. Ageing and vitamin D deficiency: effects on calcium homeostasis and considerations for vitamin D supplementation. Br J Nutr 2009; 101: 1597-1606 [PMID: 19393111 DOI: 10.1017/S0007114509338842]
162. Henry HL, Bouillon R, Norman AW, Gallagher JC, Lips P, Heaney RP, Vieth R, Pettifor JM, Dawson-Hughes B, Lamberg-Allardt CJ, Ebeling PR. 14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. J Steroid Biochem Mol Biol 2010; 121: 4-6 [PMID: 20561983 DOI: 10.1016/j.jsbmb.2010.05.008]
163. Dali-Youcef N, Andrès E. An update on cobalamin deficiency in adults. QJM 2009; 102: 17-28 [PMID: 18990719 DOI: 10.1093/qjmed/hcn138]
164. de Groot LC, Verheijden MW, de Henauw S, Schroll M, van Staveren WA. Lifestyle, nutritional status, health, and mortality in elderly people across Europe: a review of the longitudinal results of the SENECA study. J Gerontol A Biol Sci Med Sci 2004; 59: 1277-1284 [PMID: 15699526]
165. Kenney WL, Chiu P. Influence of age on thirst and fluid intake. Med Sci Sports Exerc 2001; 33: 1524-1532 [PMID: 11528342]
166. Hamer HM, De Preter V, Windey K, Verbeke K. Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol 2012; 302: G1-G9 [PMID: 22016433 DOI: 10.1152/ajpgi.00048.2011]
167. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009; 136: 2003-2014 [PMID: 19457424 DOI: 10.1053/j.gastro.2009.01.075]
168. Genser D. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab 2008; 52 Suppl 1: 29-32 [PMID: 18382075 DOI: 10.1159/000115345]
169. Karlström O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clin Infect Dis 1998; 26: 141-145 [PMID: 9455523]
170. Mäkivuokko H, Tiihonen K, Tynkkynen S, Paulin L, Rautonen N. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br J Nutr 2010; 103: 227-234 [PMID: 19703328 DOI: 10.1017/S0007114509991553]
171. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S-18S [PMID: 11755892]
172. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-896 [PMID: 12028177]
173. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-M156 [PMID: 11253156]
174. Kitajima Y, Eguchi Y, Ishibashi E, Nakashita S, Aoki S, Toda S, Mizuta T, Ozaki I, Ono N, Eguchi T, Arai K, Iwakiri R, Fujimoto K. Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. J Gastroenterol 2010; 45: 218-224 [PMID: 19882375 DOI: 10.1007/s00535-009-0147-2]
175. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014; 59: 1772-1778 [PMID: 23996808 DOI: 10.1002/hep.26716]
176. Abbatecola AM, Paolisso G, Fattoretti P, Evans WJ, Fiore V, Dicioccio L, Lattanzio F. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging 2011; 15: 890-895 [PMID: 22159778]
177. Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. Geriatr Gerontol Int 2012; 12: 388-396 [PMID: 22530761 DOI: 10.1111/j.1447-0594.2012.00851.x]
178. Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, Ma YZ, Savoye M, Rothman DL, Shulman GI, Caprio S. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 2002; 51: 1022-1027 [PMID: 11916921]
179. Sanada K, Iemitsu M, Murakami H, Gando Y, Kawano H, Kawakami R, Tabata I, Miyachi M. Adverse effects of coexistence of sarcopenia and metabolic syndrome in Japanese women. Eur J Clin Nutr 2012; 66: 1093-1098 [PMID: 22569087 DOI: 10.1038/ejcn.2012.43]
180. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care 2012; 15: 12-22 [PMID: 22108098 DOI: 10.1097/MCO.0b013e32834dd297]
181. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-5772 [PMID: 14671166]
182. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011; 9: 85 [PMID: 21749681 DOI: 10.1186/1741-7015-9-85]
183. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012; 55: 1103-1111 [PMID: 21994008 DOI: 10.1002/hep.24737]
184. Li L, Zhang L, Pan S, Wu X, Yin X. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. Dig Dis Sci 2013; 58: 2376-2382 [PMID: 23589141 DOI: 10.1007/s10620-013-2658-1]
185. Newton JL, Hollingsworth KG, Taylor R, El-Sharkawy AM, Khan ZU, Pearce R, Sutcliffe K, Okonkwo O, Davidson A, Burt J, Blamire AM, Jones D. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 2008; 48: 541-549 [PMID: 18563843 DOI: 10.1002/hep.22371]
186. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-439 [PMID: 11826420]
187. Yilmaz Y, Ozdogan O. Liver disease as a risk factor for cognitive decline and dementia: an under-recognized issue. Hepatology 2009; 49: 698 [DOI: 10.1002/hep.22752]
188. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005; 25: 1045-1050 [PMID: 15731489]
189. Abbatecola AM, Ferrucci L, Marfella R, Paolisso G. Insulin resistance and cognitive decline may be common soil for frailty syndrome. Arch Intern Med 2007; 167: 2145-2146 [PMID: 17954815 DOI: 10.1001/archinte.167.19.2145-b]
190. Koplay M, Gulcan E, Ozkan F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. J Investig Med 2011; 59: 1137-1140 [PMID: 21804402 DOI: 10.231/JIM.0b013e31822a29f5]
191. O'Leary F, Allman-Farinelli M, Samman S. Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies. Br J Nutr 2012; 108: 1948-1961 [PMID: 23084026 DOI: 10.1017/S0007114512004175]
192. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483 [PMID: 11844848]
193. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986; 59: 178-193 [PMID: 2874900]
194. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93: 1043-1065 [PMID: 8598068]
195. Liu YC, Hung CS, Wu YW, Lee YC, Lin YH, Lin C, Lo MT, Chan CC, Ma HP, Ho YL, Chen CH. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One 2013; 8: e61803 [PMID: 23626730 DOI: 10.1371/journal.pone.0061803]
196. Guzzetti S, Borroni E, Garbelli PE, Ceriani E, Della Bella P, Montano N, Cogliati C, Somers VK, Malliani A, Porta A. Symbolic dynamics of heart rate variability: a probe to investigate cardiac autonomic modulation. Circulation 2005; 112: 465-470 [PMID: 16027252]
197. Frith J, Newton JL. Autonomic dysfunction in chronic liver disease. Liver Int 2009; 29: 483-489 [PMID: 19323779 DOI: 10.1111/j.1478-3231.2009.01985.x]
198. Newton JL. Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 214-219 [PMID: 20460914 DOI: 10.1159/000282089]
199. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res 2009; 19: 319-326 [PMID: 19768633 DOI: 10.1007/s10286-009-0031-4]
200. Jakovljevic DG, Hallsworth K, Zalewski P, Thoma C, Klawe JJ, Day CP, Newton J, Trenell MI. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. Clin Sci (Lond) 2013; 125: 143-149 [PMID: 23458257 DOI: 10.1042/CS20120684]
201. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012; 379: 648-661 [PMID: 22166900 DOI: 10.1016/S0140-6736(11)61514-6]
202. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, Zoppini G, Mantovani W, Barbieri E, Byrne CD. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8: e57183 [PMID: 23451184 DOI: 10.1371/journal.pone.0057183]
203. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52: 1793-1799 [PMID: 19022158 DOI: 10.1016/j.jacc.2008.07.062]
204. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, Siebelink HM, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 2010; 122: 2538-2544 [PMID: 21126971 DOI: 10.1161/CIRCULATIONAHA.110.955542]
205. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009; 35: 277-287 [PMID: 19452403 DOI: 10.1055/s-0029-1222606]
206. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891 [PMID: 11739301]
207. de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, Bezerra LC, D'Almeida V, de Oliveira CP, Pereira LM. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37 [PMID: 23547829 DOI: 10.1186/1475-2891-12-37]
208. Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis 2014; 18: 73-89 [PMID: 24274866 DOI: 10.1016/j.cld.2013.09.005]
209. Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, Lonardo A, Malavolti M, Battistini NC, Pellegrini M, Carubbi F, Bellentani S. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol 2013; 37: 353-358 [PMID: 23273500 DOI: 10.1016/j.clinre.2012.10.009]
210. Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS, Scheimann AO. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 2012; 95: 892-900 [PMID: 22338037 DOI: 10.3945/ajcn.111.020156]
211. Fedirko V, Trichopolou A, Bamia C, Duarte-Salles T, Trepo E, Aleksandrova K, Nöthlings U, Lukanova A, Lagiou P, Boffetta P, Trichopoulos D, Katzke VA, Overvad K, Tjønneland A, Hansen L, Boutron-Ruault MC, Fagherazzi G, Bastide N, Panico S, Grioni S, Vineis P, Palli D, Tumino R, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Engeset D, Parr CL, Jakszyn P, Sánchez MJ, Barricarte A, Amiano P, Chirlaque M, Quirós JR, Sund M, Werner M, Sonestedt E, Ericson U, Key TJ, Khaw KT, Ferrari P, Romieu I, Riboli E, Jenab M. Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol 2013; 24: 2166-2173 [PMID: 23670094 DOI: 10.1093/annonc/mdt168]
212. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takachi R, Tanaka Y, Mizokami M, Tsugane S. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 2012; 142: 1468-1475 [PMID: 22342990 DOI: 10.1053/j.gastro.2012.02.018]
213. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266 [PMID: 21723839 DOI: 10.1016/j.jhep.2011.06.010]
214. Stine JG, Sateesh P, Lewis JH. Drug-induced liver injury in the elderly. Curr Gastroenterol Rep 2013; 15: 299 [PMID: 23250699 DOI: 10.1007/s11894-012-0299-8]
215. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med 2012; 28: 173-186 [PMID: 22500537 DOI: 10.1016/j.cger.2012.01.002]
216. Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37: 410-415 [PMID: 17539815]
217. Premoli A, Paschetta E, Hvalryg M, Spandre M, Bo S, Durazzo M. Characteristics of liver diseases in the elderly: a review. Minerva Gastroenterol Dietol 2009; 55: 71-78 [PMID: 19212309]
218. Estep JM, Birerdinc A, Younossi Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med 2010; 10: 166-172 [PMID: 20196730]
219. Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 1077-1084; quiz e59-e60 [PMID: 23962548]
220. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818 [PMID: 21712404 DOI: 10.1093/eurheartj/ehr158]
221. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695 [PMID: 15789367]
222. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008; 48: 662-669 [PMID: 18666246 DOI: 10.1002/hep.22402]
223. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42: 272-282 [PMID: 20171943 DOI: 10.1016/j.dld.2010.01.021]
224. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922 [PMID: 21109302 DOI: 10.1016/S0140-6736(10)61272-X]
225. Lonardo A, Loria P. If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? Dig Liver Dis 2012; 44: 451-452 [PMID: 22487461 DOI: 10.1016/j.dld.2012.02.020]
226. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-1658 [PMID: 19208350 DOI: 10.1053/j.gastro.2009.01.043]
227. Ramírez G, Briceño J, Rojas A. Statins and portal hypertension: a new pharmacological challenge. Curr Vasc Pharmacol 2012; 10: 767-772 [PMID: 22272892]
228. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27: 1654-1664 [PMID: 22849701 DOI: 10.1111/j.1440-1746.2012.07232.x]
229. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-332 [PMID: 23063971 DOI: 10.1053/j.gastro.2012.10.005]
230. Pradelli D, Soranna D, Scotti L, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 2013; 22: 229-234 [PMID: 23010949 DOI: 10.1097/CEJ.0b013e328358761a]
231. Vigna GB, Zuliani G, Fellin R. Dyslipidemias in the older subject: features, significance and treatment dilemmas. Clin Lipidol 2011; 6: 339-350
232. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
233. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Antidiabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891; quiz 892 [PMID: 23381014 DOI: 10.1038/ajg.2013.5]
234. Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87 [PMID: 23137049 DOI: 10.3109/00365521.2012.719926]
235. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615 [PMID: 22773548 DOI: 10.1136/gutjnl-2011-301708]
236. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56: e50-103 [PMID: 21144964 DOI: 10.1016/j.jacc.2010.09.001]
237. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010; 52: 2206-2215 [PMID: 21105109 DOI: 10.1002/hep.24042]
238. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32: 1211-1221 [PMID: 20955440 DOI: 10.1111/j.1365-2036.2010.04467.x]
239. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904 [PMID: 22278337 DOI: 10.1007/s00125-011-2446-4]
240. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429 [PMID: 17559148 DOI: 10.1002/hep.21661]
241. Perry RJ, Shulman GI. Treating fatty liver and insulin resistance. Aging (Albany NY) 2013; 5: 791-792 [PMID: 24304662]
242. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol 2013; 48: 491-503 [PMID: 22886508 DOI: 10.1007/s00535-012-0651-7]
243. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14 [PMID: 24206433 DOI: 10.1111/apt.12543]
244. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46 [PMID: 15537682]
245. Pérez-López FR, Chedraui P, Fernández-Alonso AM. Vitamin D and aging: beyond calcium and bone metabolism. Maturitas 2011; 69: 27-36 [PMID: 21429678 DOI: 10.1016/j.maturitas.2011.02.014]
246. D'Aversa F, Tortora A, Ianiro G, Ponziani FR, Annicchiarico BE, Gasbarrini A. Gut microbiota and metabolic syndrome. Intern Emerg Med 2013; 8 Suppl 1: S11-S15 [PMID: 23468402 DOI: 10.1007/s11739-013-0916-z]
247. Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 2014; 111: 1147-1161 [PMID: 24230488]
248. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481 [PMID: 18305141 DOI: 10.2337/db07-1403]
249. Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011; 110: 650-657 [PMID: 21281408 DOI: 10.1111/j.1365-2672.2010.04922.x]
250. Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, Bischoff SC. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 2014; 9: e80169 [PMID: 24475018 DOI: 10.1371/journal.pone.0080169]
251. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.e7 [PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]